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Abstract Background: Heterotopic ossification (HO) is a
common complication following orthopedic and trauma sur-
gery, which may have substantial negative effects on the
postoperative outcome. Angiogenesis appears to play a critical
role in heterotopic ossification. One of the involved signaling
molecules is platelet-derived growth factor (PDGF) which
may be inhibited by imatinib. Questions/Purposes: Our goal
was to prevent HO by pharmacologically interfering with the
molecular signaling pathways involved in the developmental
process. We hypothesized that by administering a proven
inhibitor of PDGF expression, heterotopic bone formation
may be prevented. Methods: The effect of imatinib on HO
formation was studied in a murine model which reliably pro-
duces islets of HO within the soft tissue following Achilles
tenotomy. The control group underwent Achilles tenotomy
only. The imatinib group received imatinib mesylate. After
trial completion, the limbs were harvested and scanned by
micro-CT. Heterotopic bone volume was then identified and
quantified. Results: The mean volume of heterotopic bone
formed in the control group was 0.976mm3 compared to
0.221 mm3 in the imatinib group. The volume of HO in the
treatment group was reduced by 85% compared to the control
group. Conclusions: The administration of imatinib was
associated with a significantly reduced volume of HO. This
may be due to the inhibitory effect of imatinib on the PDGF
signaling pathway during development of HO. Clinical
Relevance: The successful reduction of HO formation
following imatinib administration has led to further insight
concerning the pathogenesis of HO which in the future may
lead to new clinical approaches towards the prevention of HO.
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Introduction
Heterotopic ossification of muscles, tendons, and ligaments is
a widely encountered problem throughout orthopedic and
trauma surgery. Heterotopic ossification may result in joint
contracture, ankylosis, pain, spasticity, swelling, fever,
neurovascular compression, lymphedema, and pressure ulcers
leading to significant disability [7]. It is defined as the forma-
tion of mature lamellar bone in soft tissues outside of the
skeletal periosteum following local trauma or operation [12].
Patients with high-grade ossification frequently necessitate
reoperation thereby largely increasing the costs of treatment.
Pharmacological agents used to prevent the formation of
heterotopic ossification (HO) include non-steroidal anti-in-
flammatory drugs [18]. Low-dose perioperative radiation
has also been shown to be very effective at preventing HO
formation [18]. However, both prophylactic modalities have
the drawback of both impeding bone remodeling and thus
fracture healing as well as reducing the strengths of the
interface between a porous-coated device and trabecular
bone [8, 9]. Some surgeons even avoid the use of any HO
prophylaxis in favor of fracture healing or implant integra-
tion. In addition, all current therapeutical options to prevent
heterotopic ossification merely decrease the incidence, but
to this day cannot completely prevent their occurrence.
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The exact mechanism leading to HO formation is not
completely understood. During bone growth, development,
and remodeling, angiogenesis (neovascularization) as well
as osteogenesis are closely associated processes, sharing
some essential mediators. The final event in endochondral
ossification is the replacement of avascular (cartilage) tissue
by highly vascularized bone. Angiogenic stimulators in-
duced by hypoxic stress within the target tissue are a pre-
requisite for the differentiation of stem cells to chondrocytes
and subsequent heterotopic bone formation. The hypoxic
tissue/cartilage template provides a target for capillary inva-
sion and angiogenesis. Histological findings suggest that
osteoblasts and osteoprogenitor cells always develop con-
comitantly with endothelial cells in the newly formed blood
vessels at sites where new bone is formed [1, 3, 23].
The Brooker grading scale of heterotopic ossification is
based on the voluminal amount of ectopic bone. Although it
is clear that severe heterotopic ossification is not incompatible
with satisfactory functional results, several studies have shown
that functional outcome in patients suffering from heterotopic
ossification is dependent on the Brooker grade meaning that
higher Brooker grades lead to significantly poorer outcome.
Therefore, not only complete prevention—but a mere
reduction in the amount of ectopic bone formation—may
still suffice in order to significantly improve the functional
outcome in patients with heterotopic ossification.
Attempts to prevent or treat aberrant bone formation have
been restricted by the complexity and multiple causes of the
disorder. New therapies are being devised to target the induc-
tive molecules that may trigger the process, the progenitor
cells, and local tissue environments conducive to osteogenesis.
The modulation of factors thought to be associated with HO
formation like hypoxia or neovascularization has only rarely
been the target of investigations. Angiogenesis is required for
endochondral bone formation. Although the exact mecha-
nisms involved are not entirely clear, a possible explanation
could be that new vessels are necessary to bring new stem cells
into the target area where HO is about to be formed.
One of the signaling molecules involved in the process of
angiogenesis is the platelet-derived growth factor (PDGF),
which plays a key role in endochondral ossification.
Imatinib mesylate has been shown to specifically inhibit
PDGF (Glivec®, Novartis, Switzerland) [19]. The short-term
inhibition of angiogenesis as regulated by PDGF is the
property of imatinib that may limit the development of
heterotopic ossification particularly in soft tissues.
We have therefore created the hypothesis that inhibition
of new blood vessel formation resulting from blockage of
PDGF expression by imatinib may ultimately reduce or
inhibit the production of heterotopic bone. With this in
mind, the primary aim of this project was to investigate
whether imatinib could reduce the incidence and volume of
HO in a murine model of soft tissue trauma.
Materials and Methods
The study was approved by the local animal care and ethical
committees. The model used [11] is a well established
murine model in which HO formation reliably occurs within
the soft tissue of a mouse hind limb 10 weeks after soft
tissue trauma by means of an Achilles tenotomy.
Genetically unmodified CD1 mice were selected for the
study. Identification was carried out by markings on the tail.
Anesthesia was carried out using isoflurane 5–2% in oxygen
(flow rate, 400 ml/min), via nose cone. The anesthetized
mice underwent bilateral midpoint Achilles tendon
tenotomy through a posterior approach, and the skin was
closed using nonabsorbable sutures (Figs. 1 and 2). The
animals were randomly assigned to one of two groups: a
control group (n010) and a treatment group (n010). Peri-
operative analgesia was mainly achieved with paracetamol
(Dafalgan syrup 3%, 200 mg/kg), for 1–3 days [6].
To reduce stress and possible pain postoperatively, the
animals were checked several times a day according to a
predefined protocol. If they presented signs of postoperative
distress (apathy, shivering, no chow and water intake), the
treatment with paracetamol was extended. A score sheet was
developed for detection of discomfort.
The control group underwent Achilles tenotomy only.
The treatment group additionally received 10 mg/kg
imatinib p.o. daily. This corresponds to the lowest dosage
used in mice in the literature [22] over a period of 6 weeks,
followed by 4 weeks of rest and cage activity only.
At 10 weeks after surgery, the mice were euthanized and
the limbs harvested. Radiographic workup for the presence
of HO was carried out using micro-CT of the hind legs with
a nominal resolution of 30 μm (b-cube, Swiss Federal Insti-
tute of Technology, Zurich, Switzerland) (Fig. 3). First, 2D
overview images were generated. Those images showed a
series of slices through the specimen. Skeletal, as well as
ectopic, bone was separated from the background by a fixed
thresholding procedure. The heterotopic bone compartments
were then manually identified and analyzed as a separate
compartment. HO was defined as any bone within soft tissue
with a density at least equivalent to that of spongy skeletal
bone. Following this, a 3D image of each limb was created,
and the mass of heterotopic bone could be identified and
quantitatively assessed (Fig. 4). In cases of multiple foci, the
individual volumes were added together.
Fig. 1. An intraoperative caption of a skin incision performed on the
mouse hind limb.
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Statistical analysis was conducted in collaboration with
the Division of Biostatistics at the Institute for Social and
Preventive Medicine of the University of Zurich, Switzer-
land. The analysis was performed using SPSS software
(IBM, Chicago, IL). Bone volume was analyzed using de-
scriptive statistics (ANOVA), and differences between the
groups were identified using the Wilcoxon rank sum test.
Data were given as heterotopic bone volume in cubic milli-
meter, the level of significance set at p<0.05. The histolog-
ical stainings were semiquantitatively assessed.
Results
All animals survived, and there were no severe side effects;
paracetamol use and postoperative mobility were compara-
ble in the two groups. Overall, heterotopic ossifications
occurred in n035 limbs (87.5%), while in n05 limbs
(12.5%), no heterotopic bone could be found (see Figs. 3
and 4). Heterotopic bone did not form as a single continuous
mass but rather in a multitude of single independent areas.
There was no difference in the occurrence of HO be-
tween groups, but the volume of HO was reduced in the
treatment group (p00.028) In the control group, heterotopic
ossification was found in 90% of the limbs (n018) and in the
treatment group in 85% of the limbs. The volume of HO in
the control group ranged between 0.000 and 7.429 mm3 with
a median of 0.976 mm3 (SD, 1.70 mm3). The range in the
imatinib group was between 0.000 and 1.649 mm3 with a
median of 0.221 mm3 (SD, 0.42 mm3). This corresponds to a
reduction of the volume of HO by 85% and was statistically
significant (p00.028, Fig. 5). Differences could be found not
only in the total volume of HO formed, but also in the
number of independent HO areas (mean of 4.2 islets in the
treatment group vs. mean of 6 islets in the control group; see
Fig. 4). This finding, however, was not statistically
significant (p00.31).
Discussion
This study was conducted to investigate whether imatinib, a
substance which is known to specifically inhibit PDGF, is
capable of preventing HO formation in a well established
murine model, where a soft tissue trauma by means of
Achilles tenotomy reliably leads to HO formation within
Fig. 2. An intraoperative caption of the performed Achilles tenotomy.
Fig. 3. A CT scan of a left mouse hind limb where heterotopic
ossifications are marked with arrows.
Fig. 4. 3D reconstruction of a mouse hind limb with heterotopic
ossifications highlighted in yellow.
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the soft tissue of the murine hind leg. If successful, future
studies are planned to further analyze the involved signaling
pathways to reassure that this reduction was in fact coupled
with a decrease in PDGF-positive cells.
This study has its limitations. We were able to dem-
onstrate the efficacy of imatinib in the prevention of HO
formation in a soft tissue trauma model. The effect of
PDGF suppression through imatinib on fracture healing
(as it is very important with traumatic HO) has, howev-
er, not been addressed and has yet to be examined.
Future studies are to be conducted concerning this
matter.
Imatinib may have also effectively decreased ectopic
bone formation through other additional signaling pathways
not addressed in this study. In addition, it is not known how
imatinib affects wound healing or bony ingrowth with re-
spect to arthroplasty. Here, too, further studies will need to
be conducted in order to gain further insight. Lastly, it is not
clear in how far these findings in a murine model are also
applicable in humans.
Our fundamental hypothesis was that angiogenesis is a
key factor in the development of heterotopic bone. Previous
studies have proven that PDGF is one of many important
factors promoting this process, and imatinib in turn has been
demonstrated to specifically inhibit PDGF expression.
An interesting finding was that although an impressing
reduction in bone volume (85%, p00.028) could be ob-
served in the group treated with imatinib, there was no
complete prevention of the initiation of HO formation in
the treatment group. A possible explanation for this could
either be the relatively low dosage used in the trial or
other—as mentioned above—additional signaling pathways
involved. Future investigations will need to deal with potential
side effects and lowest possible dosage of the drug. The actual
dosage of 10 mg/kg daily p.o. approximately corresponds to
the dosage used in humans to treat chronic myeloid leukemia.
In mice, a tenfold dosage was initially proposed by the man-
ufacturer (email communication with product manager at
Novartis®, Switzerland).
The incomplete prevention of heterotopic ossification
corresponds to clinical findings, where heterotopic ossifica-
tion also may occur despite the use of current means of HO
prophylaxis such as radiation or NSAR. A low-volume HO
formation, however (Brooker grade 1 and 2), has showed to
be of very little clinical significance in humans.
Morphologic and biochemical analysis of the heterotopic
bone has shown an intense turnover and a high content of
multiple growth factors (including PDGF), indicating a met-
abolically active tissue [23] PDGF plays an important role in
bone metabolism, especially in the bone healing process and
reconstruction, acting as a stimulatory substance. The exact
mechanism by which PDGF is related to altered bone for-
mation is not yet completely understood. As stated earlier, a
possible explanation could be that new vessels are necessary
to bring in new stem cells into the target area where HO is
about to be formed—and our hypothesis that PDGF inhibi-
tion may ultimately also successfully inhibit heterotopic
bone formation. Imatinib mesylate inhibits PDGF-controlled
signaling pathways. This was shown in a study by Van
Steensel et al. where imatinib mesylate successfully
inhibited PDGF-BB-induced orbital fibroblast proliferation
by blocking PDGF-receptor phosphorylation [19].
As previously stated, the effects of imatinib in a fracture
healing model have yet to be investigated. Due to the com-
plexity of the multiple signaling pathways involved in frac-
ture healing, the exact influence and role of PDGF has not
yet been definitively identified, and conflicting results have
been found.
For now, promising emergent literature has already iden-
tified imatinib to be related to increased bone mineral den-
sity and bone volume with long-time use though [2, 4, 5, 10,
14, 20, 21]. These studies, however, deal with alterations of
mature bone and may not exactly reflect the situation during
callus formation and bone healing. One study [21] also
mentions a positive effect of imatinib on bone density and
volume in growing adolescent mice (using the same dosage
as in the present one), and Ranly and Roussy demonstrated
an inhibitory effect of PDGF on bone formation [16, 17].
These encouraging findings warrant further investigations
involving imatinib as an agent to inhibit ectopic bone for-
mation while at the same time possibly not impeding frac-
ture healing. In contrast, Nash and colleagues have found a
Fig. 5. Graphic comparison between heterotopic bone volume (in
cubic millimeter) in the control group and the treatment group.
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stimulative effect of PDGF on the rate of fracture healing in
rabbits[13].
We are aware that this new approach to limit HO forma-
tion is the “beginning” of a study rather than a complete
work. Nevertheless, following further research, PDGF sup-
pression might represent a valuable future alternative in the
prevention of heterotopic ossification.
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